Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: Lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice

European Neuropsychopharmacology

Volumn 19, Issue 7, 2009, Pages 466-475

  Mechanic, Jordan A ^a   Sutton, Janette E ^a   Berson, Amy E ^a   Wu, Xiaosu ^a   Kwan, Joyce ^a   Schreiber, Rudy ^a   Pang, Zhen ^a   Button, Donald C ^a  

^a Molecular Biology   (United States)

Author keywords

Antinociception; Antipsychotic; Apomorphine induced climbing; Neurotensin; Neurotensin hexapeptide analog

Indexed keywords

APOMORPHINE; NEUROLEPTIC AGENT; NEUROTENSIN RECEPTOR; NEUROTENSIN RECEPTOR 1; NT 2; NT69L; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; AUTORADIOGRAPHY; BEHAVIOR; CLIMBING; CONTROLLED STUDY; CORE TEMPERATURE; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; HYPOTHERMIA; MOUSE; NOCICEPTION; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; THERMOREGULATION;

ANALYSIS OF VARIANCE; ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; BINDING, COMPETITIVE; BODY TEMPERATURE; DOPAMINE AGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MOTOR ACTIVITY; NEUROTENSIN; OLIGOPEPTIDES; PAIN; PEPTIDE FRAGMENTS; PROTEIN BINDING; RADIOLIGAND ASSAY; REACTION TIME; RECEPTORS, NEUROTENSIN; RNA, MESSENGER; STARTLE REACTION;

EID: 67249159163     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2009.01.004     Document Type: Article

References (27)

1. Binder E.B., Kinkead B., Ownes M.J., and Nemeroff C.B. The Role of Neurotensin in the Pathophysiology of Schizophrenia and the Mechanism of Action of Antipsychotic Drugs. Biol. Pysch. 50 (2001) 856-872
2. Bolden-Watson C., Watson M.A., Murray K.D., Isackson P.J., and Richelson E. Haloperidol but not clozapine increases neurotensin receptor mRNA levels in rat substantia nigra. J. Neurochem. 61 (1993) 1141-1143
3. Breslin N.A., Suddath R.L., Bissette G., Nemeroff C.B., Lowrimore P., and Weinberger D.R. CSF concentration of neurotensin in schizophrenia: An investigation of clinical and biochemical correlates. Schizophr. Res. 12 (1994) 35-41
4. Cusack B., Boules M., Tyler B.M., Fauq A., McCormick D., and Richelson E. Effects of a novel neurotensin peptide analog given extracranially on CNS behaviors mediated by apomorphine and haloperidol. Brain Res. 856 (2000) 48-54
5. Dubuc I., Sarret P., Labbe-Jullie C., Botto J.M., Honore E., Bourdel E., Martinez J., Costentin J., Vincent J.P., Kitabgi P., and Mazella J. Identification of the receptor subtype involved in the analgesic effect of neurotensin. J. Neurosci. 19 (1999) 503-510
6. Dubuc I., Sarret P., Labbé-Jullié C., Botto J.M., Honoré E., Bourdel E., Martinez J., Costentin J., Vincent J.P., Kitabgi P., and Mazella J. Identification of the receptor subtype involved in the analgesic effect of neurotensin. Journal of Neurosci 19 (1999) 503-510
7. Garver D.L., Bissette G., Yao J.K., and Nemeroff C.B. Relation of CSF neurotensin concentrations to symptoms and drug response of psychotic patients. Am. J. Psychiatry 148 (1991) 484-488
8. Govoni S., Hong J.S., Yang H.Y., and Costa E. Increase of neurotensin content elicited by neuroleptics in nucleus accumbens. J. Pharmacol. Exp. Ther. 215 (1980) 413-417
9. Gudasheva T.A., Voronina T.A., Ostrovskaya R.U., Zaitseva N.I., Bondarenko N.A., Briling V.K., Asmakova L.S., Rozantsev G.G., and Seredenin S.B. Design of N-Acylprolyltyrosine "Tripeptoid" analogs of neurotensin as potential atypical antipsychotic agents. J. Med. Chem. 41 (1998) 284-290
10. Hertel P., Byskov L., Didriksen M., and Arnt J. Induction of tolerance to the suppressant effect of the neurotensin analog NT69L on amphetamine-induced hyperactivity. Eur. J. Pharmacol. 422 (2001) 77-81
11. Jolicoeur F.B., Gange M.A., Rivest R., Drumheller A., and St. Pierre S. Neurotensin selectively antagonizes apomorphine-induced stereotyped climbing. Pharmacol. Biochem. Behav. 38 (1991) 463-465
12. Jolicoeur F.B., Gange M.A., Rivest R., Drumheller A., and St. Pierre S. Atypical neuroleptic-like behavioral effects of neurotensin. Brain Res. Bull 32 (1993) 487-491
13. Labbe-Jullie C., Dubuc I., Brouard A., Doulut S., Bourdel E., Pelaprat D., Mazella J., Martinez J., Rostene W., Costentin J., and Kitabgi P. In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes. J. Pharmacol. Exp. Ther. 268 1 (1994) 328-336
14. Lahti R.A., Cochrane E.V., Roberts R.C., Conley R.R., and Tamminga C.A. [3H]-Neurotensin receptor densities in human postmortem brain tissue obtained from normal and schizophrenic persons. An autoradiographic study. J. Neural. Trans. 105 (1998) 507-516
15. Maeno H., Yamada K., Santo-Yamada Y., Aoki K., Sun Y.J., Sato E., Fukushimi T., Ogura H., Araki T., Kamichi S., Kimura I., Yamano M., Maeno-Hikichi Y., Watase K., Aoki S., Kiyama H., Wada E., and Wada K. Comparison of mice deficient in the high- or low-affinity neurotensin receptors, Ntsr1 or Ntsr2, reevals a novel function for Ntsr2 in thermal nociception. Brain Res. 998 (2004) 122-129
16. Merchant K.M., Dobner P.R., and Dorsa D.M. Differential effects of haloperidol and clozapine on neurotensin gene transcription in rat neostriatum. J. Neurosci. 12 2 (1992) 652-663
17. 3-neurotensin. Neuroscience 22 2 (1987) 525-536
18. Pettibone D.J., Hess J.F., Hey P.J., Jacobson M.A., Leviten M., Lis E.V., Mallorga P.J., Pascarella D.M., Snyder M.A., Williams J.B., and Zeng Z. The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin. J. Pharmacol. Exp. Ther. 300 (2002) 305-313
19. Radke J.M., Owens M.J., Ritchie J.C., and Nemeroff C.B. Atypical antipsychotic drugs selectively increase neurotensin efflux in dopamine terminal regions. Proc. Natl. Acad. Sci. 95 (1998) 11462-11464
20. Remaury A., Vita N., Gendreau S., Jung M., Arnone M., Poncelet M., Culouscou J., Le Fur G., Soubrie P., Caput D., Shire D., Kopf M., and Ferrara P. Targeted inactivation of the neurotensin type 1 receptor reveals its role in body temperature control and feeding behavior but not in analgesia. Brain Res. 953 (2002) 63-72
21. Sarhan S., Hitchcock J., Grauffel C., and Wettstein J. Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist. Peptides 18 8 (1997) 1223-1227
22. Tyler B.M., Douglas C.L., Fauq A.H., Pang Y.P., Stables J.A., Cusack B., McCormick D.J., and Richelson E. In vitro binding and CNS effects of novel neurotensin agonists that cross the blood brain barrier. Neuropharmacology 38 (1999) 1027-1034
23. Tyler B.M., Jansen K., McCormick D.J., Douglas C.L., Boules M., Stewart J.A., Zhao L., Lacy B., Cusack B., Fauq A., and Richelson E. Peptide nucleic acids targeted to the neurotensin receptor and administered intraperitoneally cross the blood brain barrier and specifically reduce gene expression. Proc. Natl. Acad. Sci. 96 (1999) 7053-7058
24. Tyler-McMahon B.M., Stewart J.A., Farinas F., McCormick D.J., and Richelson E. A highly potent neurotensin analog that crosses the blood brain barrier and causes hypothermia and antinociception. Eur. J. Pharmacol. 390 (2000) 107-111
25. Uhl G.R., and Kuhar M.J. Chronic neuroleptic treatment enhances neurotensin receptor binding in human and rat substantia nigra. Nature 309 (1984) 350-352
26. Widerlov E., Lindstrom L.H., Besev G., Manberg P.J., Nemeroff C.B., Breese G.R., Kizer J.S., and Prange A.J.J. Subnormal CSF levels of neurotensin in a subgroup of schizophrenic patients: Normalization after neuroleptic treatment. Am. J. Psychiatry 139 9 (1982) 1122-1126
27. Wolf S.S., Hyde T.M., Saunders R.C., Herman M.M., Weinberger D.R., and Kleinman J.E. Autoradiographic characterization of neurotensin receptors in the entorhinal cortex of schizophrenic patients and control subjects. J. Neural. Trans. 102 1 (1995) 55-65